GNI Group's Gyre Therapeutics files FY2024 Form 10-K

GNI Group [TSE:2160] announced that its core subsidiary, Gyre Therapeutics, Inc. (GYRE), filed its Form 10-K, equivalent to an annual securities report, with the U.S. SEC on March 17, 2025. Key highlights from the disclosure include updates on clinical trials. Top-line data from the Phase 3 clinical trial of F351 targeting liver fibrosis due to chronic hepatitis B, completed in 2024, are expected to be reported by the second quarter of 2025. Furthermore, GYRE anticipates submitting an Investigational New Drug (IND) application for the Phase 2 clinical trial of F351 targeting MASH-related liver fibrosis in the United States during the first half of 2025. GNI Group stated that if there are any material disclosures from GYRE, they will also promptly disclose it.